Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy | Zendy

Bela R. Turk | Zendy; Benjamin E. Theisen | Zendy; Christina L. Nemeth | Zendy; Joel Marx | Zendy; Xiaohai Shi | Zendy; Melissa Rosen | Zendy; Richard O. Jones | Zendy; Ann B. Moser | Zendy; Paul A. Watkins | Zendy; Gerald V. Raymond | Zendy; Carol W. Tiffany | Zendy; Ali Fatemi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy

Author(s) -

Bela R. Turk,

Benjamin E. Theisen,

Christina L. Nemeth,

Joel Marx,

Xiaohai Shi,

Melissa Rosen,

Richard O. Jones,

Ann B. Moser,

Paul A. Watkins,

Gerald V. Raymond,

Carol W. Tiffany,

Ali Fatemi

Publication year - 2017

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2016.5715

Subject(s) - adrenoleukodystrophy , heterozygote advantage , superoxide dismutase , medicine , biomarker , antioxidant , compound heterozygosity , prospective cohort study , antioxidant capacity , gastroenterology , phenotype , endocrinology , pediatrics , immunology , physiology , chemistry , biochemistry , oxidative stress , genotype , peroxisome , receptor , gene

X-linked adrenoleukodystrophy (ALD) may switch phenotype to the fatal cerebral form (ie, cerebral ALD [cALD]), the cause of which is unknown. Determining differences in antioxidant capacity and superoxide dismutase (SOD) levels between phenotypes may allow for the generation of a clinical biomarker for predicting the onset of cALD, as well as initiating a more timely lifesaving therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research